Reptilase® / Haemocoagulase

Haemocoagulase a haemocoagulant enzyme system free of any toxic protein substances and composed of two different enzymes acting on blood coagulation:

• A thrombin-like serine protease that cleaves of fibrinogen to yield Fibrinopeptide A and Fibrin I monomer (Des A-monomer). This enzyme is not inhibited by AT III-heparin complex; inhibited by 2-macroglobulin.

• A thromboplastin-like enzyme which is a metalloprotein leading to activation of FX into FXa, as soon as negatively charged phospholipids become available (at the site of a lesion). FXa converts prothrombin into thrombin which displays multiple actions on platelet aggregation, on activation of plasma factors and on fibrin formation.

PHARMACOLOGICAL ACTIVITY:
• In vitro, Haemocoagulase causes coagulation of fibrinogen by gradually splitting off fibrinopeptide A, giving rise to des-A-fibrin monomers, which polymerises end-to-end to fibrin. In the presence of platelet factor 3 Haemocoagulase activates factor X.

• In vivo, therapeutic doses of Haemocoagulase will not initiate intravasal coagulation. The desA-fibrin monomer produced by Haemocoagulase remains in solution because it forms a complex with native fibrinogen. Haemocoagulase accordingly promotes and accelerates the physiological processes of haemostasis. Haemocoagulase shortens the bleeding and coagulation time.

COMMON USE IN FINAL APPLICATIONS*:
Reptilase® injection leads to a shortening of the bleeding time and the coagulation time and thus used for haemostasis purposes since 1950s such as:

• Pulmonary bleeding
• Oral bleeding
• Traumatic bleeding
• Postoperative bleeding
• Other internal and external hemorrhages

*Please check available studies for further information